ADP-0000-001-SCR
Phase N/A
OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
ADP-0055-001-MAGE-A4-SURPASS
Phase I
OPEN TO ACCRUAL
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 as Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
SOTIO-BOXR1030
Phase I/II
OPEN TO ACCRUAL *
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors